Share this Article
Copyright: © Singapore Medical Association
Bioresorbable vascular scaffolds (BRS) have been heralded as the fourth revolution in interventional cardiology following coronary angioplasty, bare-metal stents and drug-eluting stents.(1) One of the most desirable features of BRS is their temporary presence in the vessel wall. Clinical and experimental data have shown that at three years after implantation, BRS struts were completely resorbed and replaced by connective tissue, allowing the restoration of a functional endothelium.(2) This potentially reduces the risk of late (one month to one year after implantation) or very late (more than one year after implantation) scaffold thrombosis. However, the case we herein report showed that very late scaffold thrombosis (VLScT) can still occur with BRS when the bioresorption process is advanced or nearly complete.
A 52-year-old man underwent percutaneous coronary intervention of a chronic total occlusion in his proximal left anterior descending artery with two overlapping BRS (2.5 mm × 28 mm and 3 mm × 28 mm Absorb BVS, Abbott Vascular, Santa Clara, CA, USA). He was on dual antiplatelet therapy for one year and aspirin alone thereafter. At 25 months post implantation, he presented with non-ST-segment elevation myocardial infarction without acute electrocardiography changes, which had started while he was cycling. Coronary angiography showed thrombotic occlusion in the distal scaffold (
Coronary angiograms show (a) thrombotic occlusion in the distal scaffold (black arrow), (b) angiographic filling defect due to residual thrombus following thrombectomy (white arrow) and a thin neointimal layer along the entire length of the two well-expanded bioresorbable vasscular scaffolds, including their overlapping sites (*), and (c) thrombus resolution and normal antegrade vessel flow after balloon angioplasty of the distal scaffold.
Optical coherence tomography images show (a) intraluminal thrombus (black arrow) and a malapposed scaffold strut in the thrombotic segment (black arrowhead); (b) intraluminal thrombus (black arrow) and residual scaffold ‘black boxes’, which are strut footprints filled in with connective tissue (white arrowheads in b & c); and (c) residual scaffold ‘black boxes’ and a thin neointimal layer along the entire length of the two well-expanded bioresorbable vasscular scaffolds, including their overlapping sites (*).
Early and midterm BRS thromboses have been well documented(4) and are typically due to suboptimal scaffold deployment associated with bulky scaffold struts, which in themselves may delay endothelialisation or give rise to abnormal rheological conditions favouring coagulation activation. The phenomenon of VLScT is, however, rarely reported. To our knowledge, only a dozen cases have been described worldwide in small case series(5,6) and individual case reports.(7-11) Putative mechanisms of VLScT include total discontinuation of antiplatelet therapy,(8) late scaffold recoil,(10) and other mechanical factors inducing abnormal flow, such as scaffold underexpansion, malapposed or uncovered (unendothelialised) scaffold struts,(5) and late scaffold discontinuity (due to the resorption process) causing the dislocation of strut remnants into the vessel lumen.(6,11)
In our case, the underlying thrombotic substrate could not be clearly identified due to the significant amount of residual thrombus post thrombectomy and before balloon angioplasty. However, there was a malapposed scaffold strut in the thrombotic segment (
In conclusion, thrombosis of BRS may still occur even in the late stages of the scaffold resorption process. More research is required to refine the physical properties of BRS, confirm whether cases of VLScT are truly rare, elucidate the mechanisms responsible and ascertain the optimal duration of dual antiplatelet therapy to reduce such adverse events.
1. Iqbal J, Onuma Y, Ormiston J, et al. Bioresorbable scaffolds: rationale, current status, challenges, and future. Eur Heart J 2014; 35:765-76.
2. Serruys PW, Onuma Y, Garcia-Garcia HM, et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 2014; 9:1271-84.
3. Karanasos A, Simsek C, Gnanadesigan M, et al. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. J Am Coll Cardiol 2014; 64:2343-56.
4. Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffold in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2015; 10:1144-53.
5. Karanasos A, Van Mieghem N, van Ditzhuijzen N, et al. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience. Circ Cardiovasc Interv 2015; 8:e002369.
6. Raber L, Brugaletta S, Yamajik K, et al. Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings. J Am Coll Cardiol 2015; 66:1901-14.
7. Sato T, Abdel-Wahad M, Richardt G. Very late thrombosis observed on optical coherence tomography 22 months after the implantation of a polymer-based bioresorbable vascular scaffold. Eur Heart J 2015; 36:1273.
8. Timmers L, Stella PR, Agostoni P. Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy. Eur Heart J 2015; 36:393.
9. Azzalini L, Al-Hawwas M, L'Allier P. Very late bioresorbable vascular scaffold thrombosis: a new clinical entity. EuroIntervention 2015; 11:e1-2.
10. Cortese B, Piraino D, Ielasi A, Steffenino G, Orrego PS. Very late bioresorbable vascular scaffold thrombosis due to late device recoil. Int J Cardiol 2015; 189:132-3.
11. Ielasi A, Cortese B, Steffenino G. Late structural discontinuity as a possible cause of very late everolimus-eluting bioresorbable scaffold thrombosis. JACC Cardiovasc Interv 2015; 8:e171-2.